MA31368B1 - Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens - Google Patents

Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens

Info

Publication number
MA31368B1
MA31368B1 MA32334A MA32334A MA31368B1 MA 31368 B1 MA31368 B1 MA 31368B1 MA 32334 A MA32334 A MA 32334A MA 32334 A MA32334 A MA 32334A MA 31368 B1 MA31368 B1 MA 31368B1
Authority
MA
Morocco
Prior art keywords
cyclopropylmethoxy
carboxamide
dichloro
pyridine
methoxy
Prior art date
Application number
MA32334A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Philippe Delay-Goyet
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38819821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31368(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA31368B1 publication Critical patent/MA31368B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
MA32334A 2007-04-19 2009-11-10 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens MA31368B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0702852A FR2915099B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens
PCT/FR2008/000531 WO2008145838A2 (fr) 2007-04-19 2008-04-16 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens

Publications (1)

Publication Number Publication Date
MA31368B1 true MA31368B1 (fr) 2010-05-03

Family

ID=38819821

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32334A MA31368B1 (fr) 2007-04-19 2009-11-10 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens

Country Status (33)

Country Link
US (1) US9393236B2 (he)
EP (1) EP2146713B1 (he)
JP (1) JP5386476B2 (he)
KR (1) KR101460828B1 (he)
CN (1) CN101663036B (he)
AR (1) AR066105A1 (he)
AT (1) ATE532513T1 (he)
AU (1) AU2008257319B2 (he)
BR (1) BRPI0810423A2 (he)
CA (1) CA2684171C (he)
CL (1) CL2008001135A1 (he)
CO (1) CO6140028A2 (he)
CY (1) CY1112282T1 (he)
DK (1) DK2146713T3 (he)
EA (1) EA015503B1 (he)
ES (1) ES2376023T3 (he)
FR (1) FR2915099B1 (he)
HR (1) HRP20120130T1 (he)
IL (1) IL201447A (he)
JO (1) JO2861B1 (he)
MA (1) MA31368B1 (he)
ME (2) ME00938B (he)
MX (1) MX2009011214A (he)
MY (1) MY147207A (he)
NZ (1) NZ580484A (he)
PA (1) PA8776701A1 (he)
PL (1) PL2146713T3 (he)
PT (1) PT2146713E (he)
RS (1) RS52130B (he)
SI (1) SI2146713T1 (he)
TW (1) TWI423800B (he)
UY (1) UY31034A1 (he)
WO (1) WO2008145838A2 (he)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2621894C2 (ru) * 2012-11-28 2017-06-08 Санофи Способ получения новых кристаллических форм-4(циклопропилметокси)-n-(3, 5-дихлор-1-оксидопиридин-4-ил)-5-метоксипиридин-2-карбоксамида и его кристаллические формы
WO2025079694A1 (ja) * 2023-10-12 2025-04-17 株式会社 メドレックス 経皮吸収組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1273326A (en) * 1917-08-22 1918-07-23 George H Bugenhagen Transmission mechanism.
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
EP0711282B1 (en) * 1993-07-28 2002-06-05 Aventis Pharma Limited Compounds as pde iv and tnf inhibitors
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
GB9507297D0 (en) * 1995-04-07 1995-05-31 Rh Ne Poulenc Rorer Limited New composition of matter
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
WO2000075116A2 (en) * 1999-06-07 2000-12-14 Warner-Lambert Company Tricyclic analgesics
EP1244649B1 (en) * 1999-12-23 2005-03-02 Icos Corporation Cyclic amp-specific phosphodiesterase inhibitors
CA2439691A1 (en) * 2001-03-02 2002-09-12 Bristol-Myers Squibb Company Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
WO2004005258A1 (en) 2002-07-02 2004-01-15 Merck Frosst Canada & Co. Di-aryl-substituted-ethane pyridone pde4 inhibitors
US20060083714A1 (en) * 2003-01-27 2006-04-20 Warner James M Combination of a pde iv inhibitor and a tnf-alpha antagonist
JP2007525482A (ja) 2003-10-07 2007-09-06 レノビス， インコーポレイテッド イオンチャネルリガンドとしてのアミド化合物およびその使用
CA2611562A1 (en) * 2005-06-10 2006-12-21 Memory Pharmaceuticals Corporation Trisubstituted amines as phosphodiesterase 4 inhibitors
US20070021451A1 (en) * 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury
FR2915098B1 (fr) 2007-04-19 2009-06-05 Sanofi Aventis Sa Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes de la moelle epiniere

Also Published As

Publication number Publication date
MY147207A (en) 2012-11-14
ME00938B (me) 2012-06-20
CN101663036B (zh) 2012-06-20
CA2684171C (fr) 2015-12-01
ATE532513T1 (de) 2011-11-15
JP2010524903A (ja) 2010-07-22
KR20090130058A (ko) 2009-12-17
AU2008257319B2 (en) 2013-07-25
PT2146713E (pt) 2012-02-07
CY1112282T1 (el) 2015-12-09
MX2009011214A (es) 2009-11-02
CO6140028A2 (es) 2010-03-19
WO2008145838A2 (fr) 2008-12-04
CA2684171A1 (fr) 2008-12-04
BRPI0810423A2 (pt) 2014-10-14
AR066105A1 (es) 2009-07-22
TWI423800B (zh) 2014-01-21
EA015503B1 (ru) 2011-08-30
SI2146713T1 (sl) 2012-03-30
US20100130553A1 (en) 2010-05-27
ES2376023T3 (es) 2012-03-08
RS52130B (sr) 2012-08-31
ME01273B (me) 2013-06-20
EP2146713A2 (fr) 2010-01-27
FR2915099A1 (fr) 2008-10-24
EA200970968A1 (ru) 2010-02-26
HRP20120130T1 (hr) 2012-03-31
UY31034A1 (es) 2008-11-28
JP5386476B2 (ja) 2014-01-15
JO2861B1 (en) 2015-03-15
HK1141724A1 (en) 2010-11-19
IL201447A0 (en) 2010-05-31
PL2146713T3 (pl) 2012-04-30
CN101663036A (zh) 2010-03-03
TW200914009A (en) 2009-04-01
PA8776701A1 (es) 2008-11-19
EP2146713B1 (fr) 2011-11-09
CL2008001135A1 (es) 2009-01-16
NZ580484A (en) 2011-06-30
WO2008145838A3 (fr) 2009-03-26
FR2915099B1 (fr) 2009-06-05
US9393236B2 (en) 2016-07-19
KR101460828B1 (ko) 2014-11-11
AU2008257319A1 (en) 2008-12-04
DK2146713T3 (da) 2012-03-05
IL201447A (he) 2013-07-31

Similar Documents

Publication Publication Date Title
EP1838320A4 (en) CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL PROBLEMS
FR13C0029I2 (fr) Compositions pour le traitement de troubles gastro-intestinaux
JO2701B1 (en) Vehicles
SG166820A1 (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
MY151048A (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
TW200626068A (en) Active compounds for seed treatment
MA33302B1 (fr) 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale
JO2645B1 (en) Vehicles
MA33569B1 (fr) Ligands sigma pour la prevention ou le traitement de la douleur induite par la chimiotherapie
MA31798B1 (fr) Composés organiques
DE502005005636D1 (en) Spirocyclische cyclohexan-derivate
MA31369B1 (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes de la moelle epiniere
FR2891460B1 (fr) Utilisation d'au moins un compose de la famille des avermectines pour le traitement des pathologies ophtalmiques dues au demodex folliculorum.
EP1581243A4 (en) ORAL LACTOFERRIN FOR SEPSIS TREATMENT
MA31368B1 (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens
MA31902B1 (fr) Oxazolidinones pour le traitement et/ou la prophylaxie de l'insuffisance cardiaque
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
MA33813B1 (fr) Utilisation d'une source de l3 et/ou de l5 comme vaccin ou comme diagnostic pour une maladie parasitaire
MA31367B1 (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson.
GB0611907D0 (en) Compounds
EP1732549A4 (en) METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
EP1868583A4 (en) CONTROLLED RELEASED COMPOSITIONS WITH A CEPHALOSPORIN FOR TREATING BACTERIAL INFECTIONS
FR2912059B1 (fr) Utilisation d'argiles pour le traitement de la maladie coeliaque
MA29587B1 (fr) Compositions et methodes de diagnostic et de traitement de tumeur
FR2904756B1 (fr) Dispositif de maintien des seins pour application medicale.